American Journal of Cardiology
Volume 103, Issue 10 , Pages 1417-1425 , 15 May 2009

The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications

  • Paul M. Ridker, MD, MPH

      Affiliations

    • Eugene Braunwald Professor of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Vincent E. Friedewald, MD

      Affiliations

    • Associate Editor, The American Journal of Cardiology, and Research Professor, University of Notre Dame, Notre Dame, Indiana
    • Corresponding Author InformationCorresponding author: Tel: 574-631-6675; fax: 574-631-4505
    • ,
  • Michael H. Davidson, MD

      Affiliations

    • Clinical Professor, Director of Preventive Cardiology, The University of Chicago, Pritzker School of Medicine, Chicago, Illinois
    • ,
  • James T. Willerson, MD

      Affiliations

    • President and Medical Director, Texas Heart Institute, Houston, Texas
    • ,
  • William C. Roberts, MD

      Affiliations

    • Editor-in-Chief, The American Journal of Cardiology and Baylor University Medical Center Proceedings, Executive Director, Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, Texas

References 

  1. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  2. Ridker PM, Rifai N, Pfeffer MA, Downs JR, Weis SE, Miles JS, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 2001;344:1959–1965
  3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622
  4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  5. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  6. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839–844
  7. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38
  8. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation. 2006;114:281–288
  9. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45:1644–1648
  10. Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol. 2008;28:1385–1391
  11. Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH, et al Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443

 This discussion took place on December 2, 2008.

PII: S0002-9149(09)00605-5

doi: 10.1016/j.amjcard.2009.02.023

American Journal of Cardiology
Volume 103, Issue 10 , Pages 1417-1425 , 15 May 2009

Article Tools